ALL SOURCES
Mechanism and clinical relevance of metabolic-immune cross-talk in pancreatic tumor microenvironment.
Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.
CAR T cell therapy beyond cancer: current status, challenges and future prospects.
Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killing.
Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions.
The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.
Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma.
Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。